JP2024532485A5 - - Google Patents
Info
- Publication number
- JP2024532485A5 JP2024532485A5 JP2024513933A JP2024513933A JP2024532485A5 JP 2024532485 A5 JP2024532485 A5 JP 2024532485A5 JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024532485 A5 JP2024532485 A5 JP 2024532485A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- region sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240402P | 2021-09-03 | 2021-09-03 | |
| US63/240,402 | 2021-09-03 | ||
| US202263327700P | 2022-04-05 | 2022-04-05 | |
| US63/327,700 | 2022-04-05 | ||
| PCT/US2022/075846 WO2023034922A2 (en) | 2021-09-03 | 2022-09-01 | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532485A JP2024532485A (ja) | 2024-09-05 |
| JP2024532485A5 true JP2024532485A5 (https=) | 2025-09-05 |
Family
ID=85413134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513933A Pending JP2024532485A (ja) | 2021-09-03 | 2022-09-01 | Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240383978A1 (https=) |
| EP (1) | EP4395823A4 (https=) |
| JP (1) | JP2024532485A (https=) |
| KR (1) | KR20240073008A (https=) |
| AU (1) | AU2022337286A1 (https=) |
| CA (1) | CA3230426A1 (https=) |
| WO (1) | WO2023034922A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240133746A (ko) * | 2022-01-09 | 2024-09-04 | 아이-맵 바이오파마 컴파니 리미티드 | 다중특이적 작제물 및 이의 용도 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564432A1 (en) * | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid .beta. peptide antibody and fragment of said antibody |
| EP2303924B1 (en) * | 2008-06-16 | 2016-07-27 | Patrys Limited | Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
| PT3514172T (pt) * | 2014-04-01 | 2020-04-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Imunorrecetores específicos de claudina-6 e epítopos de células t |
| EP3554544A4 (en) * | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| US10752691B2 (en) * | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| US20220177583A1 (en) * | 2019-03-20 | 2022-06-09 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| BR112021008870A2 (pt) * | 2019-08-12 | 2021-11-30 | Abl Bio Inc | Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. |
| AU2020337958A1 (en) * | 2019-08-28 | 2022-03-17 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| JP7758672B2 (ja) * | 2019-12-20 | 2025-10-22 | ノヴァロック バイオセラピューティクス， リミテッド | 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法 |
| CA3174094A1 (en) * | 2020-03-31 | 2021-10-07 | Shinya Ishii | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| US20250277026A1 (en) * | 2021-03-02 | 2025-09-04 | Novarock Biotherapeutics, Ltd. | Antibodies against claudin-6 and uses thereof |
-
2022
- 2022-09-01 EP EP22865806.8A patent/EP4395823A4/en active Pending
- 2022-09-01 CA CA3230426A patent/CA3230426A1/en active Pending
- 2022-09-01 AU AU2022337286A patent/AU2022337286A1/en active Pending
- 2022-09-01 JP JP2024513933A patent/JP2024532485A/ja active Pending
- 2022-09-01 WO PCT/US2022/075846 patent/WO2023034922A2/en not_active Ceased
- 2022-09-01 KR KR1020247008121A patent/KR20240073008A/ko active Pending
- 2022-09-01 US US18/688,630 patent/US20240383978A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532485A5 (https=) | ||
| Wu et al. | Building blocks for bispecific and trispecific antibodies | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP2023082067A (ja) | 改良された抗原結合受容体 | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| JP2023518134A5 (https=) | ||
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| JP2016514676A (ja) | 四価二重特異性抗体 | |
| CN103687879A (zh) | 多价抗原结合fv分子 | |
| JP2025508316A5 (https=) | ||
| CN115066274A (zh) | 三价结合分子 | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| TW202241956A (zh) | 新穎抗cd24抗體 | |
| Müller et al. | Bispecific Antibodies | |
| JP2024001073A5 (https=) | ||
| JP2024504162A5 (https=) | ||
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| JP2025512953A5 (https=) | ||
| CN113825772A (zh) | 抗her2亲合体及将其用作开关分子的可切换嵌合抗原受体 | |
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| JP2024541476A5 (https=) | ||
| JP2024546923A5 (https=) | ||
| JP2025505611A5 (https=) |